Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC has increased its stake in Regeneron Pharmaceuticals by 23.0%, owning approximately 0.18% of the company, valued at $120.02 million.
• Regeneron Pharmaceuticals posted $12.89 earnings per share for its latest quarter, surpassing estimates by $4.46 and resulting in a revenue of $3.68 billion.
• Analysts have a generally positive outlook on Regeneron, with an average target price of $817.67 and multiple firms issuing "buy" ratings.

Voya Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 23.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 189,244 shares of the biopharmaceutical company's stock after purchasing an additional 35,410 shares during the period. Voya Investment Management LLC owned approximately 0.18% of Regeneron Pharmaceuticals worth $120,024,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of REGN. Brighton Jones LLC raised its stake in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after purchasing an additional 686 shares during the period. American Assets Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $427,000. NorthRock Partners LLC raised its stake in Regeneron Pharmaceuticals by 90.0% during the fourth quarter. NorthRock Partners LLC now owns 802 shares of the biopharmaceutical company's stock worth $571,000 after purchasing an additional 380 shares during the period. ProShare Advisors LLC raised its stake in Regeneron Pharmaceuticals by 21.7% during the fourth quarter. ProShare Advisors LLC now owns 146,135 shares of the biopharmaceutical company's stock worth $104,096,000 after purchasing an additional 26,018 shares during the period. Finally, Raiffeisen Bank International AG purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $3,510,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of analyst reports. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Citigroup reiterated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Finally, Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target for the company. in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Up 0.4%

Shares of REGN stock traded up $2.47 during trading on Tuesday, reaching $575.06. The company's stock had a trading volume of 707,913 shares, compared to its average volume of 1,094,070. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,165.85. The company has a market capitalization of $60.95 billion, a price-to-earnings ratio of 14.49, a P/E/G ratio of 1.87 and a beta of 0.35. The stock's 50-day moving average price is $565.30 and its 200 day moving average price is $577.02.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the previous year, the business posted $11.56 EPS. The firm's revenue was up 3.6% on a year-over-year basis. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.